Compare EXK & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXK | MIRM |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.2B |
| IPO Year | 2004 | 2019 |
| Metric | EXK | MIRM |
|---|---|---|
| Price | $12.14 | $89.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $13.94 | ★ $108.92 |
| AVG Volume (30 Days) | ★ 11.4M | 613.8K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $74.46 | $24.90 |
| Revenue Next Year | $12.39 | $19.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.95 | $36.88 |
| 52 Week High | $15.15 | $109.28 |
| Indicator | EXK | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 36.78 |
| Support Level | $10.50 | $72.17 |
| Resistance Level | $12.75 | $107.51 |
| Average True Range (ATR) | 0.85 | 3.76 |
| MACD | 0.02 | -2.43 |
| Stochastic Oscillator | 45.49 | 12.71 |
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has two operating mining segments which are located in Mexico, Guanacevi and Bolanitos. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.